The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

September 22, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Many systemic sclerosis (SSc) patients may develop interstitial lung disease (ILD) and, despite a growing consensus that all patients with SSc should be screened with high-resolution chest computed tomography (CT), screening varies among rheumatology practices.1,2

You Might Also Like
  • CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
Also By This Author
  • Patients with RA Who Respond to Treatment Experience Increased Cholesterol

In March 2021, the U.S. Food & Drug Administration (FDA) approved tocilizumab to treat SSc-associated ILD. Tocilizumab, an anti-interleukin (IL) 6 agent, is the first biologic therapy to receive an indication for this condition. It also has indications for rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis and other rheumatologic conditions.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Tocilizumab Preserves Lung Function

The FDA approval of tocilizumab was based on data from two randomized controlled trials in patients with early SSc. The trials documented a large, clinically meaningful effect on forced vital capacity (FVC) and demonstrated tocilizumab preserved lung function in patients receiving therapy. This result stood in contrast to those of individuals in the placebo group, who experienced a large decline in lung function.3,4 However, the studies were limited because they did not describe radiographically evident, quantitative lung involvement.

Observational studies and clinical trials, such as the ones described above, have also shed light on the natural progression of SSc-associated ILD and the typical decline in FVC % associated with disease. In particular, the decline in the placebo group surprised experts because SSc-associated ILD is typically considered a slow progressive ILD. However, the trials documented a large and clinically meaningful average decline in FVC in the placebo group.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Focusing on Early SSC-Associated ILD

Recently, researchers reported the results of a post hoc analysis of patients from the focuSSced trial who were stratified by degree of lung involvement. The investigators used these data to analyze the effect of tocilizumab on lung function preservation in different subgroups and determine the relationship between degree of total lung involvement and fibrosis.

The researchers found patients with early SSc-associated ILD and progressive skin disease treated with tocilizumab demonstrated stabilized percent FVC at 48 weeks. The response described by David Roofeh, MD, a rheumatologist at the University of Michigan Health, Ann Arbor, Mich., and colleagues was independent of the extent of radiographically evident, quantitative ILD. The findings were published in the July issue of Arthritis & Rheumatology.4

The phase 3, multi-center, randomized, double-blind, placebo-controlled focuSSced trial, included patients with SSc who were at-risk for progressive ILD.5 All patients met the 2013 ACR/EULAR classification criteria and had disease onset of fewer than 60 months from the onset of their first non-Raynaud’s phenomenon sign or symptom, as well as a modified Rodnan skin score between 10 and 35. At baseline and week 48, the investigators performed baseline and serial spirometry along with high-resolution chest CT scans. Next, they used computer software to determine quantitative ILD and fibrosis scores. Using these baseline quantitative ILD scores, the researchers stratified patients into four groups: minimal (5% or less), mild (greater than 5–10%), moderate (greater than 10–20%) and severe (greater than 20%) lung involvement.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Results

Of the 210 participants recruited for the study, only 30% had a history of ILD at baseline, whereas the investigators diagnosed 65% with ILD following uniform high-resolution chest CT scans. Most patients with ILD had moderate to severe lung involvement and approximately one-third of the patients in the trial had severe ILD.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives Tagged With: interstitial lung disease (ILD), systemic sclerosis (SSc), systemic sclerosis-associated ILD, tocilizumab

You Might Also Like:
  • CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
  • Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)